📣 VC round data is live. Check it out!

Autobio Diagnostics Valuation Multiples

Discover Autobio Diagnostics' revenue and EBITDA valuation multiples and investment history, alongside public comparables like Ambu, Carl Zeiss Meditec, Tecan Group, Insight Lifetech and more.

Autobio Diagnostics Overview

About Autobio Diagnostics

Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company’s main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.


Founded

1999

HQ

China

Employees

5.8K

Financials (LTM)

Revenue: $639M
EBITDA: $247M

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Autobio Diagnostics Financials

Autobio Diagnostics reported last 12-month revenue of $639M and EBITDA of $247M.

In the same LTM period, Autobio Diagnostics generated $418M in gross profit, $247M in EBITDA, and $161M in net income.

Revenue (LTM)


Autobio Diagnostics P&L

In the most recent fiscal year, Autobio Diagnostics reported revenue of $625M and EBITDA of $251M.

Autobio Diagnostics is profitable as of last fiscal year, with gross margin of 66%, EBITDA margin of 40%, and net margin of 25%.

See analyst estimates for Autobio Diagnostics
LTMLast FY202320242025202620272028
Revenue$639M$625M$657M$661M$625M
Gross Profit$418M$410M$427M$432M$410M
Gross Margin65%66%65%65%66%
EBITDA$247M$251M$272M$264M$251M
EBITDA Margin39%40%41%40%40%
EBIT Margin28%28%29%28%27%
Net Profit$161M$158M$180M$177M$158M
Net Margin25%25%27%27%25%

Financial data powered by Morningstar, Inc.

Autobio Diagnostics Stock Performance

Autobio Diagnostics has current market cap of $3B, and enterprise value of $3B.

Market Cap Evolution


Autobio Diagnostics' stock price is $4.70.

Autobio Diagnostics share price decreased by 4.9% in the last 30 days, and by 13.7% in the last year.

Autobio Diagnostics has an EPS (earnings per share) of $0.28.

See more trading valuation data for Autobio Diagnostics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$3B-1.0%-4.9%-4.2%-13.7%$0.28

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Autobio Diagnostics Valuation Multiples

Autobio Diagnostics trades at 4.0x EV/Revenue multiple, and 10.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Autobio Diagnostics

EV / Revenue (LTM)


Autobio Diagnostics Financial Valuation Multiples

As of June 3, 2026, Autobio Diagnostics has market cap of $3B and EV of $3B.

Autobio Diagnostics has a P/E ratio of 16.7x.

LTMLast FY202320242025202620272028
EV/Revenue4.0x4.1x3.9x3.9x4.1x
EV/EBITDA10.3x10.1x9.4x9.6x10.1x
EV/EBIT14.0x14.5x13.3x13.6x15.0x
EV/Gross Profit6.1x6.2x6.0x5.9x6.2x
P/E16.7x17.0x14.9x15.2x17.0x
EV/FCF9.2x8.1x30.3x26.8x23.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Autobio Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Autobio Diagnostics Margins & Growth Rates

Autobio Diagnostics grew revenue by 7% and EBITDA by 2% in the last fiscal year.

In the most recent fiscal year, Autobio Diagnostics reported gross margin of 66%, EBITDA margin of 40%, and net margin of 25%.

See estimated margins and future growth rates for Autobio Diagnostics

Autobio Diagnostics Margins

Last FY202420252026202720282029
Gross Margin66%65%66%65%
EBITDA Margin40%40%40%38%
EBIT Margin28%28%27%28%
Net Margin25%27%25%25%
FCF Margin50%14%17%34%

Autobio Diagnostics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%1%(5%)7%
Gross Profit Growth6%1%(5%)6%
EBITDA Growth2%(3%)(5%)2%
EBIT Growth8%(2%)(9%)12%
Net Profit Growth6%(2%)(11%)6%
FCF Growth(29%)13%14%106%

Data powered by FactSet, Inc. and Morningstar, Inc.

Autobio Diagnostics Operational KPIs

Autobio Diagnostics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.

Autobio Diagnostics' Rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Autobio Diagnostics' Rule of X is 56% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Autobio Diagnostics
LTMLast FY202320242025202620272028
Rule of 4048%45%---
Bessemer Rule of X62%56%---
Revenue per Employee-$0.1M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue20%20%7%7%8%
G&A Expenses to Revenue6%6%1%1%1%
R&D Expenses to Revenue13%13%15%16%13%
Opex to Revenue-38%36%37%38%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Autobio Diagnostics Competitors

Autobio Diagnostics competitors include Ambu, Carl Zeiss Meditec, Tecan Group, Insight Lifetech, Double Medical Technology, Sinbon Electronics, TransMedics, Haemonetics, MGI Tech and Integer Holdings.

Most Autobio Diagnostics public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Ambu2.8x2.7x14.6x14.7x
Carl Zeiss Meditec1.1x1.1x6.5x7.4x
Tecan Group2.1x2.1x14.0x13.9x
Insight Lifetech29.2x-131.6x-
Double Medical Technology5.9x5.6x16.4x13.9x
Sinbon Electronics2.3x2.3x15.9x17.6x
TransMedics4.6x4.2x17.0x17.4x
Haemonetics3.0x3.0x10.1x10.0x

This data is available for Pro users. Sign up to see all Autobio Diagnostics competitors and their valuation data.

Start Free Trial

Investments by Autobio Diagnostics

Autobio Diagnostics has invested in 1 company to date.

Latest investment by Autobio Diagnostics was on December 17th 2018. Autobio Diagnostics invested in Mobidiag in their $12M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Autobio Diagnostics

Mobidiag
Description
Mobidiag is a Keilaranta-headquartered Finnish-French biotechnology company offering qPCR and microarray tests for gastrointestinal infections, antibiotic resistance, HAIs, respiratory pathogens, and sepsis. Its automated platforms like Novodiag serve labs from small clinics to high-volume centers across Europe and beyond.
HQ CountryFinland
HQ City
Espoo
Deal Date17 Dec 2018
RoundSeries A
Raised$12M
InvestorsAutobio Diagnostics
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Autobio Diagnostics investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Autobio Diagnostics

When was Autobio Diagnostics founded?Autobio Diagnostics was founded in 1999.
Where is Autobio Diagnostics headquartered?Autobio Diagnostics is headquartered in China.
How many employees does Autobio Diagnostics have?As of today, Autobio Diagnostics has over 5K employees.
Is Autobio Diagnostics publicly listed?Yes, Autobio Diagnostics is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Autobio Diagnostics?Autobio Diagnostics trades under 603658 ticker.
When did Autobio Diagnostics go public?Autobio Diagnostics went public in 2016.
Who are competitors of Autobio Diagnostics?Autobio Diagnostics main competitors include Ambu, Carl Zeiss Meditec, Tecan Group, Insight Lifetech, Double Medical Technology, Sinbon Electronics, TransMedics, Haemonetics, MGI Tech, Integer Holdings.
What is the current market cap of Autobio Diagnostics?Autobio Diagnostics' current market cap is $3B.
What is the current revenue of Autobio Diagnostics?Autobio Diagnostics' last 12 months revenue is $639M.
What is the current revenue growth of Autobio Diagnostics?Autobio Diagnostics revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of Autobio Diagnostics?Current revenue multiple of Autobio Diagnostics is 4.0x.
What is the current EBITDA of Autobio Diagnostics?Autobio Diagnostics' last 12 months EBITDA is $247M.
What is Autobio Diagnostics' EBITDA margin?Autobio Diagnostics' last 12 months EBITDA margin is 39%.
What is the current EV/EBITDA multiple of Autobio Diagnostics?Current EBITDA multiple of Autobio Diagnostics is 10.3x.
What is the current FCF of Autobio Diagnostics?Autobio Diagnostics' last 12 months FCF is $276M.
What is Autobio Diagnostics' FCF margin?Autobio Diagnostics' last 12 months FCF margin is 43%.
What is the current EV/FCF multiple of Autobio Diagnostics?Current FCF multiple of Autobio Diagnostics is 9.2x.
How many companies Autobio Diagnostics has acquired to date?Autobio Diagnostics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Autobio Diagnostics has invested to date?As of June 2026, Autobio Diagnostics has invested in 1 company.
What was the last Autobio Diagnostics investment?On 17th December 2018 Autobio Diagnostics invested in Mobidiag, participating in a $12M Series A round.
In what companies Autobio Diagnostics invested in?Autobio Diagnostics invested in Mobidiag.

See public comps similar to Autobio Diagnostics

Lists including Autobio Diagnostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial